Baseline data
| Variable . | M-CHIP . | No M-CHIP . | All patients . | P value . |
|---|---|---|---|---|
| Patients who had NGS before first CLL treatment (cohort A) | ||||
| n | 92 (12%) | 655 (88%) | 747 (100%) | - |
| Age at diagnosis, y (median, IQR) | 65 (59-73) | 61 (53-68) | 62 (54-68) | <.0001 |
| Age at NGS testing, y (median, IQR) | 67 (62-75) | 64 (57-71) | 64 (57-72) | .0001 |
| Age (y) category (% of age group with M-CHIP) | .0004 | |||
| <40 | 0 (0%) | 14 (100%) | 14 | |
| 40-50 | 3 (5%) | 59 (95%) | 62 | |
| 50-60 | 15 (8%) | 158 (92%) | 173 | |
| 60-70 | 35 (13%) | 241 (87%) | 276 | |
| 70-80 | 25 (14%) | 152 (86%) | 177 | |
| >80 | 14 (31%) | 31 (69%) | 45 | |
| Days from diagnosis to NGS (median, IQR) | 178 (31-803) | 246 (50-1332) | 225 (49-1265) | .13 |
| Sex (F) | 34 (37%) | 266 (41%) | 300 (40%) | .50 |
| IGHV mutation status | .15 | |||
| Mutated | 39 (42%) | 342 (52%) | 381 (51%) | |
| Unmutated | 47 (51%) | 265 (40%) | 312 (42%) | |
| Failed/unknown | 6 (7%) | 48 (7%) | 54 (7%) | |
| Cytogenetics (present/absent)∗ | .11 | |||
| 17pdel | 11 (12%) | 56 (8%) | 67 (9%) | |
| Deletion 11q | 13 (14%) | 61 (9%) | 74 (10%) | |
| Deletion 13q | 30 (33%) | 288 (44%) | 318 (43%) | |
| Trisomy 12 | 23 (25%) | 116 (18%) | 139 (19%) | |
| Normal | 21 (23%) | 158 (24%) | 179 (24%) | |
| 17p deletion or TP53 mutation | 16 (17%) | 95 (15%) | 113 (15%) | .47 |
| Prior non-CLL therapy | .76 | |||
| ITP-related medication (steroids and/or rituximab and/or romiplostim) | 2 (2%) | 7 (1%) | 9 (1%) | |
| Immunotherapy (for solid tumor) | 0 (0%) | 1 (0.2%) | 1 (0.1%) | |
| Chemotherapy (for solid tumor) | 0 (0%) | 1 (0.2%) | 1 (0.1%) | |
| Patients who had NGS after treatment (cohort B) | ||||
| n | 52 (24%) | 167 (76%) | 219 (100%) | - |
| Age (y) at diagnosis (median, IQR) | 60 (53-66) | 55 (48-4) | 56 (50-64) | .08 |
| Age (y) at NGS testing (median, IQR) | 69 (61-77) | 66 (59-73) | 67 (60-74) | .12 |
| Age (y) category (% of age group with M-CHIP) | .64 | |||
| <40 | 1 (33%) | 2 (67%) | 3 | |
| 40-50 | 1 (17%) | 5 (83%) | 6 | |
| 50-60 | 8 (17%) | 39 (83%) | 47 | |
| 60-70 | 18 (22%) | 64 (78%) | 82 | |
| 70-80 | 18 (22%) | 40 (69%) | 58 | |
| >80 | 6 (26%) | 17 (74%) | 23 | |
| Days from diagnosis to NGS (median, IQR) | 3679 (1953-5023) | 3356 (1806-5021) | 3339 (1824-5021) | .66 |
| Sex (F) | 14 (27%) | 56 (33%) | 70 (32%) | .37 |
| IGHV mutation status | .57 | |||
| Mutated | 12 (23%) | 51 (30%) | 63 (29%) | |
| Unmutated | 35 (67%) | 100 (60%) | 135 (62%) | |
| Failed/unknown | 5 (10%) | 16 (10%) | 21 (9%) | |
| Cytogenetics (present/absent)∗ | .41 | |||
| 17pdel | 13 (25%) | 32 (19%) | 45 (21%) | |
| Deletion 11q | 7 (13%) | 34 (20%) | 41 (19%) | |
| Deletion 13q | 15 (29%) | 55 (33%) | 70 (32%) | |
| Trisomy 12 | 10 (19%) | 18 (11%) | 28 (13%) | |
| Normal | 16 (31%) | 50 (30%) | 66 (30%) | |
| 17p deletion or TP53 mutation | 20 (39%) | 46 (28%) | 66 (30%) | .13 |
| Prior chemotherapy exposure | 44 (85%) | 119 (71%) | 163 (74%) | .02 |
| Prior lines of therapy | .52 | |||
| 1 | 20 (38%) | 83 (50%) | 103 (47%) | |
| 2 | 13 (25%) | 33 (20%) | 46 (21%) | |
| 3 | 7 (13%) | 22 (13%) | 29 (13%) | |
| ≥4 | 12 (23%) | 29 (17%) | 41 (19%) |
| Variable . | M-CHIP . | No M-CHIP . | All patients . | P value . |
|---|---|---|---|---|
| Patients who had NGS before first CLL treatment (cohort A) | ||||
| n | 92 (12%) | 655 (88%) | 747 (100%) | - |
| Age at diagnosis, y (median, IQR) | 65 (59-73) | 61 (53-68) | 62 (54-68) | <.0001 |
| Age at NGS testing, y (median, IQR) | 67 (62-75) | 64 (57-71) | 64 (57-72) | .0001 |
| Age (y) category (% of age group with M-CHIP) | .0004 | |||
| <40 | 0 (0%) | 14 (100%) | 14 | |
| 40-50 | 3 (5%) | 59 (95%) | 62 | |
| 50-60 | 15 (8%) | 158 (92%) | 173 | |
| 60-70 | 35 (13%) | 241 (87%) | 276 | |
| 70-80 | 25 (14%) | 152 (86%) | 177 | |
| >80 | 14 (31%) | 31 (69%) | 45 | |
| Days from diagnosis to NGS (median, IQR) | 178 (31-803) | 246 (50-1332) | 225 (49-1265) | .13 |
| Sex (F) | 34 (37%) | 266 (41%) | 300 (40%) | .50 |
| IGHV mutation status | .15 | |||
| Mutated | 39 (42%) | 342 (52%) | 381 (51%) | |
| Unmutated | 47 (51%) | 265 (40%) | 312 (42%) | |
| Failed/unknown | 6 (7%) | 48 (7%) | 54 (7%) | |
| Cytogenetics (present/absent)∗ | .11 | |||
| 17pdel | 11 (12%) | 56 (8%) | 67 (9%) | |
| Deletion 11q | 13 (14%) | 61 (9%) | 74 (10%) | |
| Deletion 13q | 30 (33%) | 288 (44%) | 318 (43%) | |
| Trisomy 12 | 23 (25%) | 116 (18%) | 139 (19%) | |
| Normal | 21 (23%) | 158 (24%) | 179 (24%) | |
| 17p deletion or TP53 mutation | 16 (17%) | 95 (15%) | 113 (15%) | .47 |
| Prior non-CLL therapy | .76 | |||
| ITP-related medication (steroids and/or rituximab and/or romiplostim) | 2 (2%) | 7 (1%) | 9 (1%) | |
| Immunotherapy (for solid tumor) | 0 (0%) | 1 (0.2%) | 1 (0.1%) | |
| Chemotherapy (for solid tumor) | 0 (0%) | 1 (0.2%) | 1 (0.1%) | |
| Patients who had NGS after treatment (cohort B) | ||||
| n | 52 (24%) | 167 (76%) | 219 (100%) | - |
| Age (y) at diagnosis (median, IQR) | 60 (53-66) | 55 (48-4) | 56 (50-64) | .08 |
| Age (y) at NGS testing (median, IQR) | 69 (61-77) | 66 (59-73) | 67 (60-74) | .12 |
| Age (y) category (% of age group with M-CHIP) | .64 | |||
| <40 | 1 (33%) | 2 (67%) | 3 | |
| 40-50 | 1 (17%) | 5 (83%) | 6 | |
| 50-60 | 8 (17%) | 39 (83%) | 47 | |
| 60-70 | 18 (22%) | 64 (78%) | 82 | |
| 70-80 | 18 (22%) | 40 (69%) | 58 | |
| >80 | 6 (26%) | 17 (74%) | 23 | |
| Days from diagnosis to NGS (median, IQR) | 3679 (1953-5023) | 3356 (1806-5021) | 3339 (1824-5021) | .66 |
| Sex (F) | 14 (27%) | 56 (33%) | 70 (32%) | .37 |
| IGHV mutation status | .57 | |||
| Mutated | 12 (23%) | 51 (30%) | 63 (29%) | |
| Unmutated | 35 (67%) | 100 (60%) | 135 (62%) | |
| Failed/unknown | 5 (10%) | 16 (10%) | 21 (9%) | |
| Cytogenetics (present/absent)∗ | .41 | |||
| 17pdel | 13 (25%) | 32 (19%) | 45 (21%) | |
| Deletion 11q | 7 (13%) | 34 (20%) | 41 (19%) | |
| Deletion 13q | 15 (29%) | 55 (33%) | 70 (32%) | |
| Trisomy 12 | 10 (19%) | 18 (11%) | 28 (13%) | |
| Normal | 16 (31%) | 50 (30%) | 66 (30%) | |
| 17p deletion or TP53 mutation | 20 (39%) | 46 (28%) | 66 (30%) | .13 |
| Prior chemotherapy exposure | 44 (85%) | 119 (71%) | 163 (74%) | .02 |
| Prior lines of therapy | .52 | |||
| 1 | 20 (38%) | 83 (50%) | 103 (47%) | |
| 2 | 13 (25%) | 33 (20%) | 46 (21%) | |
| 3 | 7 (13%) | 22 (13%) | 29 (13%) | |
| ≥4 | 12 (23%) | 29 (17%) | 41 (19%) |
P values correspond to comparing M-CHIP vs no–M-CHIP groups.
Boldface indicates significant P value of <0.05.
CLL, chronic lymphocytic leukemia; F, female; IGHV, immunoglobulin heavy chain variable region; IQR, interquartile range; ITP, immune thrombocytopenia; M-CHIP, myeloid clonal hematopoeisis of indeterminate potential; NGS, next-generation sequencing; y, years.
Cytogenetics at time closest to NGS date in cases in which there was no intervening treatment between the 2 tests.